Beth Taylor Net Worth

The estimated Net Worth of Beth Taylor is at least $836 mil dollars as of 5 March 2021. Ms. Taylor owns over 5,000 units of Basis Global Technologies Inc stock worth over $563,810 and over the last 9 years she sold BASI stock worth over $272,289. In addition, she makes $0 as Chief Financial Officer y Vice President - Finance at Basis Global Technologies Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Taylor BASI stock SEC Form 4 insiders trading

Beth has made over 6 trades of the Basis Global Technologies Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently she bought 5,000 units of BASI stock worth $88,500 on 5 March 2021.

The largest trade she's ever made was exercising 48,854 units of Basis Global Technologies Inc stock on 17 December 2018 worth over $210,561. On average, Beth trades about 5,490 units every 62 days since 2016. As of 5 March 2021 she still owns at least 34,295 units of Basis Global Technologies Inc stock.

You can see the complete history of Ms. Taylor stock trades at the bottom of the page.

Beth Taylor biography

Beth A. Taylor serves as Chief Financial Officer, Vice President - Finance of the Company. Ms. Taylor served as Vice President – Finance at Vibenomics, Inc., a location-based audio experience and out-of-home advertising business, and also engaged in consulting. Previously Ms. Taylor held progressively responsible financial and accounting leadership positions at Endocyte, Inc., a Novartis company, Author Solutions, Inc., Harlan Laboratories, Inc., Republic Airways Holdings and Rolls-Royce Corporation. Most recently, Ms. Taylor served as Vice President, Finance and Chief Accounting Officer, from August of 2016 through August of 2019, and Corporate Controller, from January of 2011 through August of 2016, at Endocyte, Inc., a Novartis company, a biopharmaceutical company and developer of targeted therapies for the personalized treatment of cancer. Ms. Taylor began her career in audit at Deloitte & Touche and holds a degree in accounting from Indiana University, Kelly School of Business, Bloomington.

How old is Beth Taylor?

Beth Taylor is 54, she's been the Chief Financial Officer y Vice President - Finance of Basis Global Technologies Inc since 2020. There are 2 older and 1 younger executives at Basis Global Technologies Inc. The oldest executive at Basis Global Technologies Inc is Richard Johnson, 70, who is the Independent Director.

What's Beth Taylor's mailing address?

Beth's mailing address filed with the SEC is C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE, IN, 47906-1382.

Insiders trading at Basis Global Technologies Inc

Over the last 21 years, insiders at Basis Global Technologies Inc have traded over $266,443 worth of Basis Global Technologies Inc stock and bought 540,162 units worth $1,698,287 . The most active insiders traders include Jacqueline M Lemke, Robert Jr. Leasure y William D Pitchford. On average, Basis Global Technologies Inc executives and independent directors trade stock every 65 days with the average trade being worth of $128,544. The most recent stock trade was executed by Beth Taylor on 5 March 2021, trading 5,000 units of BASI stock currently worth $88,500.

What does Basis Global Technologies Inc do?

Complete history of Ms. Taylor stock trades at Basis Global Technologies Inc

Basis Global Technologies Inc executives and stock owners

Basis Global Technologies Inc executives and other stock owners filed with the SEC include:

• Wendy Perrow,
  Independent Director
• R. Matthew Neff,
  Independent Director
• Richard Johnson,
  Independent Director
• Joseph Flynn,
  Chief Commercial Officer
• John Sagartz,
  Chief Strategy Officer, Director
• Connie Dougherty,
  Vice President - Business Development
• I.M. Grossi,
  Vice President - Toxicology
• Philip Downing,
  Vice President - Preclinical Services
• Andrew Alexander,
  Vice President - Pharmacology and Toxicology Operations
• Michael Baim,
  Vice President - Bioanalytical Operations
• Beth Taylor,
  Chief Financial Officer, Vice President - Finance
• Robert Leasure,
  President, Chief Executive Officer, Director
• Gregory Davis,
  Interim Chairman of the Board
• Jill Blumhoff,
  VP, Finance & CFO
• John P Devine,
  VP--Toxicology
• James Sevall Bourdage,
  VP, Bioanalytical Services
• Jacqueline M Lemke,
  CFO & Vice President--Finance
• Jeffrey Potrzebowski,
  VP, Finance & CFO
• John Gregory Beattie,
  Chief Operating Officer
• Peterkissinger Candice B Ki...,
  
• Daniel Thomas Oakley,
  Chief Operating Officer
• Kimberly L Sagartz,
  10% owner
• Chrysalis, Llc Sw,
  10% owner
• Lori Payne,
  VP Bioanalytical Services
• Larry Steven Boulet,
  Director
• David W Crabb,
  Director
• John B. Landis,
  Director
• David L Omachinski,
  Director
• Anthony S Chilton,
  COO, Scientific Studies
• A. Charlene Sullivan,
  Director
• Alberto F Jr Hidalgo,
  VP, Bus. Development & Mrkting
• Leslie B Daniels,
  Director
• Kathleen Hodges,
  Vice President of Quality
• Lina L Reeves Kerner,
  V.P. - Human Resources
• Richard M Shepperd,
  President & Chief Exec. Off.
• Ronald E Shoup,
  Chief Operating Officer
• Craig S Bruntlett,
  Sr. V.P. International Sales
• Jon Brewer,
  VP Sales/Marketing
• William E Baitinger,
  Director
• Candice B Kissinger,
  Vice President
• Margaret B Mcclure,
  Dir, Pharmaceutical Lab. Div.
• Michael R Cox,
  V.P. Finance, CFO
• Emilio Cordova,
  V.P. of Business Development
• Edward Chait,
  Executive Vice President
• Gerry Henningsen,
  Director BAS Evansville
• Donnie A Evans,
  Vice President Engineering
• Garyl W Doster,
  Director
• Michael P Silvon,
  Vice President
• Michael S Noone,
  Dir. of Clinical Affairs, Balt
• William Sawyers,
  Laboratory Director
• William D Pitchford,
  Chief HR Officer